€78.10
1.70% today
Madrid, Apr 03, 05:16 pm CET
ISIN
ES0169501022
Symbol
PHM
Sector
Industry

Pharma Mar Target price 2025 - Analyst rating & recommendation

Pharma Mar Classifications & Recommendation:

Buy
50%
Hold
33%
Sell
17%

Pharma Mar Price Target

Target Price €87.10
Price €79.45
Potential
Number of Estimates 6
6 Analysts have issued a price target Pharma Mar 2026 . The average Pharma Mar target price is €87.10. This is higher than the current stock price. The highest price target is
€118.00 48.52%
register free of charge
, the lowest is .
A rating was issued by 6 analysts: 3 Analysts recommend Pharma Mar to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Pharma Mar stock has an average upside potential 2026 of . Most analysts recommend the Pharma Mar stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million € 174.86 198.96
10.57% 13.78%
EBITDA Margin 5.34% 26.14%
1,960.35% 389.38%
Net Margin 14.98% 33.55%
2,146.02% 123.96%

6 Analysts have issued a sales forecast Pharma Mar 2025 . The average Pharma Mar sales estimate is

€199m
Unlock
. This is
13.78% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€288m 64.84%
Unlock
, the lowest is
€143m 18.28%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €175m 10.57%
2025
€199m 13.78%
Unlock
2026
€254m 27.45%
Unlock
2027
€440m 73.65%
Unlock
2028
€504m 14.40%
Unlock
2029
€597m 18.56%
Unlock

4 Analysts have issued an Pharma Mar EBITDA forecast 2025. The average Pharma Mar EBITDA estimate is

€52.0m
Unlock
. This is
456.75% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€95.0m 917.13%
Unlock
, the lowest is
€1.0m 89.29%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €9.3m 2,178.05%
2025
€52.0m 456.75%
Unlock
2026
€84.8m 62.98%
Unlock
2027
€166m 95.87%
Unlock

EBITDA Margin

2024 5.34% 1,960.35%
2025
26.14% 389.38%
Unlock
2026
33.42% 27.85%
Unlock
2027
37.70% 12.81%
Unlock

3 Pharma Mar Analysts have issued a net profit forecast 2025. The average Pharma Mar net profit estimate is

€66.7m
Unlock
. This is
156.51% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€115m 343.22%
Unlock
, the lowest is
€30.2m 16.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €26.2m 2,383.33%
2025
€66.7m 154.79%
Unlock
2026
€98.3m 47.21%
Unlock

Net Margin

2024 14.98% 2,146.02%
2025
33.55% 123.96%
Unlock
2026
38.75% 15.50%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share 1.49 3.80
2,383.33% 155.03%
P/E 20.93
EV/Sales 6.50

3 Analysts have issued a Pharma Mar forecast for earnings per share. The average Pharma Mar EPS is

€3.80
Unlock
. This is
156.76% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
€6.56 343.24%
Unlock
, the lowest is
€1.72 16.22%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €1.49 2,383.33%
2025
€3.80 155.03%
Unlock
2026
€5.59 47.11%
Unlock

P/E ratio

Current 53.51 89.69%
2025
20.93 60.89%
Unlock
2026
14.22 32.06%
Unlock

Based on analysts' sales estimates for 2025, the Pharma Mar stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.39 196.79%
2025
6.50 12.08%
Unlock
2026
5.10 21.54%
Unlock
2027
2.94 42.41%
Unlock
2028
2.57 12.59%
Unlock
2029
2.16 15.66%
Unlock

P/S ratio

Current 7.99 146.32%
2025
7.02 12.11%
Unlock
2026
5.51 21.54%
Unlock
2027
3.17 42.41%
Unlock
2028
2.77 12.59%
Unlock
2029
2.34 15.66%
Unlock

Current Pharma Mar Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RX SECURITIES
Locked
Locked
Locked Jan 05 2025
CHARDAN CAPITAL MARKETS
Locked
Locked
Locked Oct 30 2024
ALANTRA EQUITIES
Locked
Locked
Locked Oct 29 2024
NEEDHAM & COMPANY INC.
Locked
Locked
Locked Oct 29 2024
CAIXABANK BPI
Locked
Locked
Locked Sep 22 2024
Analyst Rating Date
Locked
RX SECURITIES:
Locked
Locked
Jan 05 2025
Locked
CHARDAN CAPITAL MARKETS:
Locked
Locked
Oct 30 2024
Locked
ALANTRA EQUITIES:
Locked
Locked
Oct 29 2024
Locked
NEEDHAM & COMPANY INC.:
Locked
Locked
Oct 29 2024
Locked
CAIXABANK BPI:
Locked
Locked
Sep 22 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today